• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (pts) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 Results

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Halperin, D. M.
    Johnson, M. L.
    Chan, J. A.
    Hart, L. L.
    Cook, Natalie
    Patel, V. M.
    Schlecter, B. L.
    Cave, J.
    Dowlati, A.
    Blaszkowsky, L. S.
    Meyer, T.
    Eads, J. R.
    Culp, D.
    Kriksciukaite, K.
    Mei, L.
    Bilodeau, M.
    Bloss, J.
    Kulke, M. H.
    Show allShow less
    Affiliation
    The University of Texas MD Anderson Cancer Center, Houston, TX
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    BACKGROUND: PEN-221 is a small molecule drug conjugate composed of a SSTR2 binding somatostatin analog linked to the toxin DM1. PEN-221-001 was a study which assessed the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of PEN-221 in well differentiated neuroendocrine tumors (NETs) and small cell lung cancer. METHODS: Pts with advanced, SSTR2+ GI mid-gut NETs were enrolled in this cohort of study PEN-221-001. The primary objective was to determine the safety and efficacy of PEN-221 given intravenously, every (q) 3 weeks. Preliminary efficacy was assessed using RECIST 1.1. A clinically meaningful efficacy result was defined as a Clinical Benefit Rate (CBR) > 75% and a median progression-free survival (mPFS) > 8 months. RESULTS: 32 patients were enrolled between January 2018 to June 2020 and the data cut-off for this report is July 31, 2020. The mean number of cycles received was 7 (range 1-18), with 5 pts still on treatment at time of data lock. PEN-221 was well tolerated in all pts at the dose of 8.8 mg/m2. The most frequent (≥20% pts) PEN-221 related adverse events were nausea (50%), fatigue (47%), diarrhea (47%), decreased appetite (47%), peripheral neuropathy (34%), infusion reaction (31%), AST/ Alk Phos/ALT increase (28/25/22%), and anemia (25%). Only 11 (34%) of these events were ≥grade 3. Of the 26 pts who were evaluable for response, 23 (88.5%) had stable disease (SD) reported as their best response with a CBR of 88.5%. Target lesion shrinkage was observed in 10 (38%) patients. The mPFS for this cohort was 9 months (CI 5 - 16.5 months). Tumor marker data will also be presented. CONCLUSION: PEN-221 appears well tolerated at 8.8 mg/m2 q 3 weeks and has demonstrated efficacy exceeding its clinical efficacy goals with a CBR of 88.5% and a mPFS of 9 months.
    Citation
    Halperin DM, Johnson ML, Chan JA, Hart LL, Cook N, Patel VM, et al. The Safety and Efficacy of PEN-221 Somatostatin Analog (SSA)-DM1 Conjugate in Patients (Pts) With Advanced GI Mid-gut Neuroendocrine Tumor (NET): Phase 2 Results. Pancreas. 2022 Mar;51(3):E37-E. PubMed PMID: WOS:000819123700038.
    Journal
    Pancreas
    URI
    http://hdl.handle.net/10541/625477
    Type
    Meetings and Proceedings
    Language
    en
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.